Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03979339
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:26.980654+00:00
Published At
2021-10-13T00:00:00+00:00
Record Updated At
2021-10-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2-positive Metastatic Breast Cancer", "Ovarian Cancer", "Hormone-resistant Prostate Cancer", "Circulating Tumor Cell"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-10-13"
protocolSection.identificationModule.nctId
"NCT03979339"
protocolSection.identificationModule.officialTitle
"Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • HER2-positive Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Hormone-resistant Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Circulating Tumor Cell (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.